Paul Tudor Jones Morphic Holding, Inc. Transaction History

Tudor Investment Corp Et Al

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$26.12 - $34.07 $23,037 - $30,049	-882 Reduced 3.41%	25,002 $851,000
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $689,549 - $1.04 Million	25,884 New	25,884 $911,000
Q3 2023 Nov 15, 2023	BUY	$21.33 - $59.42 $312,804 - $871,394	14,665 New	14,665 $335,000
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $51,135 - $95,724	1,966 Added 10.27%	21,115 $795,000
Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $462,256 - $581,555	19,149 New	19,149 $512,000
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $178,640 - $256,354	-4,928 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $213,234 - $323,868	4,928 New	4,928 $233,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.